Sign in
Taking peoplePhase 2/3

Efficacy of Tadalafil (5mg) For Treatment of Early Storage Symptoms and Erectile Dysfunction After Endoscopic Enucleation of Prostate

Key facts

Who runs it
Mansoura University
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 2/3
People taking part
110 people, planned
Started
1 Apr 2023
Planned end
Jul 2025
Type of study
Interventional, 2 groups
Treatments tested
  • Tadalafil 5mg / Placebo
Record updated
11 June 2025

Who can take part

Age
40 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Patients' age ≥ 40 years
  • LUTS secondary to BOO due to BPH who failed medical treatment
  • International prostate symptom scores (IPSS) >15 and bother score (QOL) ≥ 3 (according to IPSS question 8)
  • Peak urinary flow rate (Qmax) <15 ml/sec
  • ASA (American society of anaesthesiologists) score ≤ 3
  • Sexually active men, not receiving PDE5I

Who cannot take part

  • Patients with unstable angina pectoris, recent myocardial infarction or stroke myocardial insufficiency
  • Patients with severe hepatic or renal insufficiency
  • Patients with uncontrolled diabetes mellitus or neurologic condition(eg. parkinsoism)
  • Patients using nitrates, potassium channel opener, or α1-blockers doxazosin and terazosin for control of hypertension
  • Patients who are sexually inactive

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 40 and 80 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

From previous studies, the investigators found that sexual outcomes after prostate surgery may show insignificant improvement, remain unchanged or deteriorate in non-negligible number of patients especially those with high preoperative IIEF scores. Deterioration of erectile function could be attributed to persistence of storage symptoms specially nocturia. Several pathophysiologic mechanisms, described before, are involved in pathogenesis of LUTS and ED and one can imagine that after relief of obstruction, the erectile function should improve, however lack of improvement or even deterioration suggests that damage associated with these mechanisms is irreversible and patients may require some sort of penile rehabilitation after surgery.

Read full original descriptionShow less

The investigators hypothesized that Tadalafil may enhance relief of storage symptoms and enhance recovery of erectile function after surgery for BPH. With this assumption, a RCT was designed to examine the utility and efficacy of Tadalafil, once daily dose, to relieve persistent/ de novo storage symptoms and early erectile function deterioration after endoscopic prostate surgery.

The 2 groups in the trial

  • Tadalafil 5 mg dailyTreatment being tested

    those patients will receive Tadalafil 5 mg daily after HoLEP

    Treatment: Tadalafil 5mg / Placebo

  • PlaceboTreatment being tested

    Those patients will receive Placebo after HoLEP

    Treatment: Tadalafil 5mg / Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized Controlled Trial to Examine the Utility of Tadalafil (5mg) For Treatment of Early Storage Symptoms and Erectile Dysfunction After Anatomical Endoscopic Enucleation of Prostate (AEEP)
Criteria questions
Built from NCT05955001, who can take part
Record updated
11 June 2025